Euroespes, S.A. Reports Earnings Results for the Full Year Ended December 31, 2020
April 29, 2021
Share
Euroespes, S.A. Announced earnings results for the full year ended December 31, 2020. For the full year, the company announced sales was EUR 260,108 compared to EUR 876,617 a year ago. Operating loss was EUR 346,537 compared to EUR 885,276 a year ago. Net loss was EUR 411,344 compared to EUR 1.258 million a year ago.
Euroespes SA is a Spain-based company engaged in the healthcare sector. The Company operates a medical center, which focuses on the prevention, diagnosis and treatment of central nervous system disorders, such as Alzheimer and Parkinson, and other common diseases. The Companyâs medical offer includes personalized treatment plans, genomic medicine, epigenetics, neuropsychology, neuro-ophthalmology, digital diagnosis, diagnostic imaging, clinical analysis and nursing services, among others. In addition, it provides pharmacogenetics services and Human Identification Genetics card, which identifies user's deoxyribonucleic acid (DNA) profile. The Company operates through a number of subsidiaries, such as in Euroespes Biotecnologia SA, Distribuidora de Productos SL and Ebiotec Pharma SL.
EUROESPES, S.A. 
